Equities Analysts Set Expectations for EWTX FY2026 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Stock analysts at HC Wainwright issued their FY2026 earnings estimates for Edgewise Therapeutics in a research report issued on Thursday, February 26th. HC Wainwright analyst L. Egana-Gorrono forecasts that the company will post earnings of ($2.02) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ FY2027 earnings at ($2.46) EPS, FY2028 earnings at ($2.05) EPS, FY2029 earnings at ($1.11) EPS and FY2030 earnings at $2.30 EPS.

Edgewise Therapeutics (NASDAQ:EWTX) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.04).

A number of other brokerages have also recently commented on EWTX. Stifel Nicolaus set a $25.00 target price on shares of Edgewise Therapeutics in a research report on Thursday, February 26th. Piper Sandler reaffirmed an “overweight” rating on shares of Edgewise Therapeutics in a research note on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Wednesday, January 21st. Royal Bank Of Canada raised their target price on shares of Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Finally, Evercore restated an “outperform” rating and issued a $45.00 price target on shares of Edgewise Therapeutics in a research report on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.36.

Edgewise Therapeutics Trading Down 3.0%

NASDAQ:EWTX opened at $28.81 on Monday. The stock has a 50 day moving average of $27.94 and a two-hundred day moving average of $21.49. Edgewise Therapeutics has a 12 month low of $10.60 and a 12 month high of $31.82. The firm has a market cap of $3.09 billion, a P/E ratio of -17.67 and a beta of 0.26.

Insider Activity at Edgewise Therapeutics

In other news, Director Badreddin Edris sold 115,471 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the sale, the director owned 19,820 shares of the company’s stock, valued at approximately $583,500.80. This represents a 85.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 23.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EWTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Edgewise Therapeutics by 6.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,776 shares of the company’s stock worth $963,000 after acquiring an additional 2,463 shares during the last quarter. Jones Financial Companies Lllp acquired a new stake in Edgewise Therapeutics during the 1st quarter worth $47,000. Goldman Sachs Group Inc. grew its position in Edgewise Therapeutics by 5.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 366,644 shares of the company’s stock worth $8,066,000 after purchasing an additional 19,753 shares during the last quarter. Strs Ohio purchased a new position in Edgewise Therapeutics during the 1st quarter worth $84,000. Finally, Teacher Retirement System of Texas increased its stake in Edgewise Therapeutics by 10.7% in the second quarter. Teacher Retirement System of Texas now owns 12,646 shares of the company’s stock valued at $166,000 after purchasing an additional 1,225 shares during the period.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.